Deconstructing Exceptional Responses to Immune Checkpoint Inhibition in Recurrent or Metastatic Head and Neck Carcinoma: A Site-Specific Clinical-Biological Synthesis.

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

Keytruda (pembrolizumab) - Merck (MSD)

http://www.ncbi.nlm.nih.gov/pubmed/42738312

Francesco Chiari; Giovanni Motta; Giuseppe Tortoriello; Pasquale Capasso; Piero Giuseppe Meliante

Sep 16, 2026